Registry update — unassessed
The Effect of Metformin Treatment on Surrogate Markers of Ageing (Leukocyte Telomere Length and Telomerase Activity), Longevity Gene Expression (Sirtuin 1, p66Shc, p53, Andmammalian Target of Rapamycin ), in North Indian Individuals With the Prediabetes: A Randomized Control Trial
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 24, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- This is a study protocol with no reported outcomes—it describes what was planned, not what was found; no conclusions about metformin's effects can be drawn from this document alone.
- Sample size, effect sizes, and statistical significance are not provided, making it impossible to assess the magnitude or reliability of any findings.
- This is a protocol document, not a published results paper, so the trial may not have been completed or the results may not have been made available.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 6 months
- Population
- Pre-diabetic individuals from North India
- Primary outcome
- Leukocyte telomere length and telomerase activity
- Effect size
- —
- Significance
- Not reported
- Journal
- Diabetes Foundation, India
- Published
- Dec 24, 2025
Sources
Primary source
- Diabetes Foundation, India ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This clinical trial aims to evaluate the effects of metformin treatment on surrogate markers of ageing (leukocyte telomere length and telomerase activity), in the setting of pre-diabetes. We intend to compare treatment with metformin for six months, versus placebo in pre-diabetic subjects. We will assess the surrogate markers of ageing (leukocyte telomere length and telomerase activity) and the expression of longevity genes SIRT1, p66Shc, p53 and mTOR in peripheral blood mononuclear cells (PBMCs) before and after 6 months of metformin treatment.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.